Harrow (NASDAQ:HROW) Shares Up 3.9% - Here's What Happened

Harrow, Inc. (NASDAQ:HROW - Get Free Report)'s share price was up 3.9% on Friday . The stock traded as high as $28.18 and last traded at $28.27. Approximately 118,540 shares were traded during mid-day trading, a decline of 76% from the average daily volume of 494,871 shares. The stock had previously closed at $27.20.

Analysts Set New Price Targets

Several research analysts recently weighed in on HROW shares. B. Riley dropped their target price on shares of Harrow from $69.00 to $65.00 and set a "buy" rating for the company in a report on Tuesday, April 1st. HC Wainwright upped their target price on shares of Harrow from $57.00 to $60.00 and gave the stock a "buy" rating in a report on Monday, May 12th.

Harrow Price Performance

The company has a market cap of $1.04 billion, a P/E ratio of -30.04 and a beta of 0.41. The company has a debt-to-equity ratio of 3.23, a quick ratio of 1.44 and a current ratio of 1.55. The firm's fifty day moving average is $25.18 and its two-hundred day moving average is $30.30.

Harrow (NASDAQ:HROW - Get Free Report) last announced its quarterly earnings results on Thursday, May 8th. The company reported ($0.38) EPS for the quarter, missing the consensus estimate of $0.02 by ($0.40). The company had revenue of $47.83 million during the quarter, compared to analysts' expectations of $57.00 million. Harrow had a negative return on equity of 45.57% and a negative net margin of 19.75%. As a group, analysts anticipate that Harrow, Inc. will post -0.53 earnings per share for the current fiscal year.

Institutional Trading of Harrow

Several hedge funds have recently bought and sold shares of HROW. Barclays PLC lifted its stake in Harrow by 301.9% in the 3rd quarter. Barclays PLC now owns 52,593 shares of the company's stock worth $2,365,000 after purchasing an additional 39,506 shares in the last quarter. Sonora Investment Management Group LLC purchased a new stake in Harrow in the 4th quarter worth $518,000. China Universal Asset Management Co. Ltd. lifted its stake in Harrow by 10.7% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 7,552 shares of the company's stock worth $253,000 after purchasing an additional 727 shares in the last quarter. Calamos Advisors LLC lifted its stake in Harrow by 35.2% in the 4th quarter. Calamos Advisors LLC now owns 11,913 shares of the company's stock worth $400,000 after purchasing an additional 3,103 shares in the last quarter. Finally, Bleakley Financial Group LLC lifted its stake in Harrow by 63.1% in the 4th quarter. Bleakley Financial Group LLC now owns 8,770 shares of the company's stock worth $294,000 after purchasing an additional 3,394 shares in the last quarter. Hedge funds and other institutional investors own 72.76% of the company's stock.

Harrow Company Profile

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.